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Sensory attenuation in Parkinson’s 
disease is related to disease 
severity and dopamine dose
Noham Wolpe  1,2,3, Jiaxiang Zhang  2,4, Cristina Nombela 1,2, James N. Ingram 3,5,6, 
Daniel M. Wolpert  3,5,6, Cam-CAN* & James B. Rowe 1,2,3
Abnormal initiation and control of voluntary movements are among the principal manifestations of 
Parkinson’s disease (PD). However, the processes underlying these abnormalities and their potential 
remediation by dopamine treatment remain poorly understood. Normally, movements depend on the 
integration of sensory information with the predicted consequences of action. This integration leads to 
a suppression in the intensity of predicted sensations, reflected in a ‘sensory attenuation’. We examined 
this integration process and its relation to dopamine in PD, by measuring sensory attenuation. Patients 
with idiopathic PD (n = 18) and population-derived controls (n = 175) matched a set of target forces 
applied to their left index finger by a torque motor. To match the force, participants either pressed with 
their right index finger (‘Direct’ condition) or moved a knob that controlled a motor through a linear 
potentiometer (‘Slider’ condition). We found that despite changes in sensitivity to different forces, 
overall sensory attenuation did not differ between medicated PD patients and controls. Importantly, 
the degree of attenuation was negatively related to PD motor severity but positively related to 
individual patient dopamine dose, as measured by levodopa dose equivalent. The results suggest 
that dopamine could regulate the integration of sensorimotor prediction with sensory information to 
facilitate the control of voluntary movements.
A key manifestation of Parkinson’s disease (PD) is bradykinesia – that is, patients have slowness associated with 
marked difficulties in planning, initiating and executing voluntary movements1. This principal abnormality in 
motor control has been shown to correlate well with dopamine disruption in patients2, however, the exact mecha-
nism remains poorly understood. In order to better understand the mechanisms underlying movement disorders, 
previous studies have used the framework of optimal control theory3–5.
According to this theory, normal motor control depends on the integration of peripheral sensory information 
with predictions arising from internal models of action. The integration is dependent on the relative uncertainty 
(i.e. the inverse of ‘precision’) of sensory information and predictions6, such that in a highly uncertain environ-
ment, for example, people’s movements rely more on prediction7. Dopamine has been suggested to play a central 
role in regulating the precision of sensory information relative to predictions8. Striatal dopamine deficit, which is 
a hallmark pathological feature in PD, is therefore expected to lead to reduced reliance on sensory information, 
which has indeed been demonstrated in decision-making tasks9,10. However, a common clinical observation in 
PD is that patients are more dependent on sensory cues for initiating movements11. For example, the withdrawal 
of visual feedback impairs patients more than healthy individuals in terms of both movement speed and accu-
racy12. These findings suggest that striatal dopamine deficit in PD could have a different impact on representing 
sensory uncertainty for movement. Here, we examine the integration between sensory signals and prediction for 
movement in PD, through sensorimotor attenuation.
Sensorimotor attenuation is the reduction in the perceived intensity of stimuli generated by one’s actions, 
compared to externally generated stimuli. It reflects the suppression of predicted sensory consequences from 
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perception13. Intact precision of sensorimotor predictions are thought to be required for increasing the salience of 
external events, to facilitate the rapid initiation14 and correction of movements to unpredicted events6. In schizo-
phrenia, for example, reduced sensory attenuation and ‘exaggerated’ increase in reliance on sensory information 
have been suggested to contribute to deficits in distinguishing between self-caused and external stimuli15. Deficits 
in the integration of prior prediction and sensory information, as reflected in sensory attenuation, can therefore 
shed light on the mechanism of neurological and psychiatric disorders16,17.
Sensory attenuation can be quantified by the force matching task. In the force matching task18, 98% of adults 
show attenuation19, applying a larger force when matching an external force directly with their hand (‘Direct’ 
condition). In contrast, people tend to be accurate when matching the force indirectly with a linear potentiometer 
that controls a motor18. The overcompensation of forces in the Direct condition is associated with the integrity of 
a fronto-striatal network19 that is strongly affected by dopamine deficits in PD (e.g. Lewis et al.20).
We tested patients with idiopathic PD on a force matching task to measure sensory attenuation. Patient meas-
ures were compared to normative data from a large epidemiological control cohort21. Patients were tested while 
‘on’, after taking their regular dopaminergic medication, and we took advantage of the variability in disease sever-
ity and medication to examine between-subject differences in attenuation in the Direct condition in relation 
to motor severity of PD and dopamine dose. Sensory sensitivity and task-related bias were measured using the 
Slider condition. Our principal hypothesis was that with increasing motor severity, attenuation would be reduced, 
reflecting abnormal integration of sensory information with sensorimotor prediction22. We also hypothesised that 
dopaminergic medication would increase attenuation, expressing increased reliance on motor prediction.
Materials and Methods
Participants. Eighteen patients (12 men; aged 48–81 years, mean: 67; SD: 10) were recruited from the John 
van Geest Centre for Brain Repair, Parkinson’s disease research clinic. Patients met clinical diagnostic criteria 
of idiopathic PD, according to the UK PD brain bank criteria23, and were in the mild to moderate stages of dis-
ease [Hoehn and Yahr stages 1 to 3]24. Normative, population-derived controls were drawn from the Cambridge 
Centre for Ageing and Neuroscience (https://camcan-archive.mrc-cbu.cam.ac.uk/dataaccess/) using the same 
apparatus. Control subjects were selected from the data repository by age, such that all subjects within the patient 
age range were included in the study (n = 175, 89 men, mean age: 65, SD: 10). The research was carried out in 
accordance with guidelines and regulations approved by the Cambridgeshire 2 Research Ethics Committee (now 
‘East of England – Cambridge Central’), who approved the experimental protocols. All participants gave full, 
informed, written consent before the experiment.
Assessment of motor and cognitive features in patients was performed at the beginning of the testing ses-
sion. The severity of motor features was assessed with the Unified Parkinson’s Disease Rating Scale, motor sub-
scale III25. Cognition was assessed with the Mini-Mental State Examination26 and Addenbrooke’s Cognitive 
Examination Revised27, excluding patients with ACE-R score below 84/10028. Patients were tested in the morning 
after taking their medication as normal. The time interval between levodopa self-administration and testing var-
ied between one and three hours, such that all patients were in a relative ‘on’ state at the time they were assessed. 
Levodopa dose equivalent (LDE) was computed according to Tomlinson et al.29. Clinical data were collected and 
scored independently and blind to the behavioural results.
Force matching task procedures and analyses. On each trial of the Force Matching Task18, a lever 
attached to a torque motor applied the target force for 2.5 s to the left index finger (Fig. 1). The target force was 
pseudo-randomly selected from the set: 1.0, 1.5, 2.0 and 2.5 Newton (N): each target force was presented once 
within a cycle of four trials. At the end of the presentation period, the force was removed, and participants used 
Figure 1. Force matching task illustration. Illustration of the force matching task. In each trial, a torque motor 
pseudorandomly applied one of four force levels (target force) through a lever to the participants’ left index 
finger. Participants were asked to match the force they had just sensed (matched force) either by pressing the 
lever with their right index finger (‘Direct’ condition); or by sliding a linear potentiometer which controlled the 
torque motor (‘Slider’ condition).
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their right index finger to match the force they had just sensed on their left finger (matching period 4.5 sec long). 
Premature (response during the presentation period) or late (>1 s) responses led to a warning “too fast” or “too 
slow” on the computer screen, and the trial was repeated. Because PD patients have altered force output [e.g. 
increased force irregularities and time to peak30], the matched force was calculated as the mean force measured 
within a 500 ms time window that was selected on a trial-by-trial basis. A sliding window was used to identify 
the 500 ms interval that had the minimum force variability. This procedure was implemented in both patient and 
control data.
There were two conditions. In the Direct condition, participants matched the target force by pressing with 
their right index finger directly on top of the lever, mechanically transmitting the force to the left finger. In the 
Slider condition, participants matched the force with their right index finger by moving a slider (a linear poten-
tiometer) which controlled the torque motor. A force sensor at the end of the lever measured both the target and 
matched forces applied to the left finger. All participants performed both the Direct and Slider conditions, in a 
counterbalanced order. For each condition, an initial familiarisation phase of eight trials (two cycles of the four 
target forces) was performed. The main experiment for each condition consisted of 32 trials.
For each condition, mean force overcompensation was calculated as the average difference between the 
matched and the target force on each trial across the four target force levels. Positive mean overcompensation in 
the Direct condition reflected an overall attenuation of self-generated sensations. In the Slider condition, mean 
overcompensation was used to measure general task-related bias. To examine force matching as a function of 
force levels, the intercept and slope from a linear regression of matched versus target force was calculated for 
each participant and condition. The Slider slope was used as a measure of sensory sensitivity for distinguish-
ing between the different forces, reflecting sensory precision19. All statistical tests of behavioural data were per-
formed with two-tailed tests, implemented with ‘R’ software31. Given the unequal sample size32, non-parametric 
Mann-Whitney test was used for the comparison between groups. After assessing the normality of errors using 
Kolmogorov-Smirnoff test, within PD group tests were performed with parametric tests. To examine the rela-
tionship between sensory attenuation and clinical variables in the PD group, multiple regression analyses were 
conducted with Direct force overcompensation as the dependent variables. This variable was used as this measure 
most closely reflects sensory attenuation18; it does not assume a linear relationship between matched and target 
force; it has been compared in various population groups15; and it has been associated with fronto-striatal circuits 
impaired in PD19. The independent variables were disease severity and patient LDE. Covariates of no interest were 
included to account for differences in sensory inflow and motor outflow, namely: Slider slope as a measure of sen-
sory sensitivity19, mean within-trial force variability and unexplained variance of each patient linear regression of 
matched versus target force. All variables were Z-scaled before entering the model.
Results
Participant demographics. Patient clinical information is summarised in Table 1. Patients (n = 18) and 
controls (n = 175) were not different in terms of age (Mann-Whitney test; Z = 0.92, p = 0.36) and gender (χ2 = 
1.64, p = 0.2).
No. Gender Age
Disease 
duration 
(years) Side*
Disease 
stage**
UPDRS 
motor 
subscale
ACE-R 
(MMSE)
LDE 
***
1 M 63 11 R 1.5 16 94 (29) 1315
2 M 74 16 L 2 19 98 (30) 620
3 M 81 15 L 2.5 20 94 (29) 410
4 M 54 15 L 1 26 89 (29) 1815
5 M 56 11 R 3 14 86 (29) 1210
6 F 73 13 B 2.5 13 95 (28) 565
7 F 76 9 R 3 13 91 (30) 855
8 F 81 13 L 2 16 97 (29) 1355
9 M 77 13 L 2 37 97 (30) 1720
10 M 64 6 L 1.5 15 94 (29) 1175
11 M 48 6 R 2.5 24 88 (29) 535
12 M 72 26 L 1 21 85 (28) 460
13 M 57 14 B 1 21 94 (28) 1180
14 F 66 17 L 2 21 95 (27) 1740
15 M 76 12 L 1 31 87 (27) 1500
16 F 64 11 B 3 19 96 (28) 1000
17 M 77 9 L 3 18 88 (27) 700
18 F 55 8 L 2 16 98 (29) 200
Average 67 13 2 20 93 (29) 1020
Table 1. Summary of patient clinical information. UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE 
= Mini-Mental State Examination; ACE-R = Addenbrooke’s Cognitive Examination Revised; LDE = Levodopa 
dose equivalent; *Dominant side of motor symptoms: L = left, R = right, B = bilateral. **According to Hoehn 
and Yahr, 1967; ***Calculated according to Tomlinson et al.29.
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Sensory attenuation in PD. In order to calculate the matched force for each participant and trial, we 
calculated the mean force during a 500 ms interval that had the minimum force variability, found with a sliding 
window. There was no significant difference between initiation times of force matching in patients and controls 
(Mann-Whitney test; Z = −1.58, p = 0.11). Importantly the mean time at which patients and controls stabi-
lised the force after initiation was not different (2.67 s versus 2.73 s in patients and controls; Mann-Whitney 
test; Z = −0.37, p = 0.71). In the Slider condition, initiation times of force matching were similar across groups 
(Z = 1.39, p = 0.16), and patients stabilised the forces slower than controls (2.61 s versus 2.36 s in patients and 
controls; Mann-Whitney test; Z = 2.78, p  <  0.01). The distributions of calculated mean overcompensation 
(mean difference between matched and target force) for both conditions in patients were not different from 
normal distribution (one-sample Kolmogorov-Smirnov test; Direct: D = 0.228, p = 0.26, Slider: D = 0.137, p 
= 0.845).
All patients showed overall sensory attenuation, as indicated by a positive mean overcompensation in the 
Direct condition (Fig. 2A). Mean Direct force overcompensation was greater than zero (t17 = 6.94, p  <  SD = 
0.92 N). Patients were more accurate when matching the force in the Slider condition (Fig. 2A), with smaller force 
overcompensation than in the Direct condition (t17 = −5.93, p  <  0.001). Mean Slider force overcompensation 
was −0.01 N (SD = 0.36 N), and was not significantly different from zero (t17 = −0.12, p = 0.91). These results 
confirm that sensory attenuation is as robust in PD patients as in the general population19. Direct and Slider force 
overcompensation were not correlated in patients (r(16) = 0.29, p = 0.24), supporting the notion of a distinct 
underlying mechanism for sensory attenuation in the Direct condition.
To examine changes in attenuation in PD, we compared overall attenuation and attenuation as a function of 
force levels in patients with our age-matched, normative control data. There were no significant differences in 
mean Direct force overcompensation (Mann-Whitney test; Z = 1.00, p = 0.32), suggesting no group difference in 
overall attenuation. Similarly, no group differences emerged in mean Slider overcompensation (Z = −0.45, p = 
0.65).
To compare force matching as a function of force level, we examined the linear regression fits of target force 
versus matched force (Fig. 2B). These linear regression fits may well change for a different range of forces, but 
provide a local approximation for the force stimuli used in the experiment. As there were no group differences 
in mean overcompensation in the Direct and Slider conditions, these measures provide more details on possible 
Figure 2. Differences in sensorimotor attenuation between PD patients and controls. (A) Standard boxplots 
showing the distribution of mean force overcompensation values across all patients and controls in the Direct 
(shades of blue) and Slider (shades of red) conditions. Positive value indicates sensory attenuation. (B) Mean 
regression plots of matched versus target force in the Direct and Slider conditions for both groups. Colour 
scheme is the same as in (A). Dashed line indicates the line of equality. Error bars indicate ± 2 standard error of 
group mean. Control data points and error bars are offset by 2 pixels for illustration.
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differences in the force matching procedure, namely: (i) differences in sensitivity to the target forces, reflected in 
varying levels of overcompensation across force levels and changes in the slope; and (ii) differences in response 
bias across all forces, reflected in a different intercept with normal slope.
The linear regression fit was better in controls, with patients showing smaller R2 compared to controls in both 
conditions (Direct: Z = 2.37, p  <  0.05; Slider: Z = 3.30, p  <  0.001). In the Direct condition, there was an increase 
in the intercept in patients compared to controls (Mann-Whitney test; Z = 2.25, p  <  0.05, Bonferroni corrected), 
with no significant difference in the slope (Z = −1.8, p = 0.14, Bonferroni corrected). In the Slider condition, 
patients showed both reduced slope (Mann-Whitney test; Z = −2.82, p  <  0.01, Bonferroni corrected) and a 
corresponding increase in intercept (Z = 2.75, p  <  0.01, Bonferroni corrected). These results suggest reduced 
sensitivity to the different forces in patients in the Slider condition, but not in the Direct condition, as also found 
in relation to ageing19. We therefore accounted for these differences in the next analyses.
Before testing how sensory attenuation might be related to clinical features in patients, we conducted several 
control analyses to verify the patients’ abilities to match the forces in the Direct condition. Compared to con-
trols, patients showed increased within-trial variability in the forces they applied (Mann-Whitney test; Z = 2.72, 
p  <  0.01), consistent with previous findings in PD30. This is likely to arise from reduced force sensitivity due to 
increased sensory variability33, which, importantly, is not expected to introduce a systematic bias given the nature 
of the force matching task (see Discussion). However, increased within-trial force variability could also arise from 
the patients ‘overshooting’ and then slowly adjusting the force; an impaired ability to decide what force to apply; 
and/or from difficulties maintaining a steady force due to fatigue.
To explore the possibility of a systematic bias in the matching procedure, we performed additional analyses. 
First, for each trial, within the analysed time window, we fit a linear regression model of matched force against 
time. There was no linear trend in the matched force (regression slope not significantly different from zero; t17 = 
−0.96, p = 0.35), similar to controls (Mann-Whitney test; Z = 0.53, p = 0.53). Moreover, there was no consist-
ent relationship between this linear trend and the magnitude of the force applied by each patient (mean Pearson 
correlation coefficient not different from zero in patients; t17 = −1.41, p = 0.18), which was again similar to 
controls (Mann-Whitney; Z = 0.15, p = 0.25). These results suggest it is unlikely that patients fatigued in the 
force they applied. Further, although not significantly different from controls, the slope in the Direct condition 
was overall smaller in patients relative to controls (see Fig. 2B). This raises the possibility that patients were 
more limited in their ability to match larger forces. However, a closer look at the Direct slope demonstrated it 
was not significantly different from a veridical slope of one (Wilcoxon signed-rank test; Z = −1.76, p = 0.08). 
To further explore patient performance in matching larger forces, we computed the Pearson coefficient of the 
correlation between the magnitude of matched forces and within-trial SD for each trial and for each subject. 
There was a consistently positive relationship between the matched force and within-trial SD in patients (mean 
Pearson correlation coefficient significantly greater than zero across patients; t17 = 8.09, p  <  0.001), consistent 
with the well-known association between generated force variability and force level34. Importantly, however, 
this association did not differ from controls (Mann-Whitney test; Z = −1.21, p = 0.23). Taken together, these 
control analyses suggest that PD did not alter the matching procedure itself. Nevertheless, we accounted for 
group differences in matching procedure (within-trial variability and R2 of the matched against target force) in 
the next analysis.
Dopamine and sensory attenuation. To examine the relationship between sensory attenuation and 
patient dopamine dose, we next fit a linear regression model with Direct force overcompensation as the depend-
ent variable. The independent variables were disease severity, as assessed using the Unified Parkinson’s disease 
Rating Scale motor subscale III, and levodopa dose equivalent (LDE; Tomlinson et al.29). To control for basic 
sensory and motor differences affecting the force matching procedure in patients, we included additional covari-
ates of no interest. These were the Slider slope measuring sensory sensitivity19, patient force variability and unex-
plained variance of each patient linear fits (see Methods).
The regression model was statistically significant (F(5,12) = 3.24, p  <  0.05; 40% of force overcompensation 
variance explained; Fig. 3A). Even though disease severity and LDE were marginally positively correlated (r(16) = 
0.46, p = 0.056), they had opposite effects on Direct overcompensation in patients. Disease severity was a negative 
predictor (t12 = −2.62, p  <  0.05), whereas LDE was a positive predictor (t12 = 2.51, p  <  0.05). For illustration, 
the direct relationship between attenuation and dopamine dose is plotted in Fig. 3B. This pattern of results did not 
change when additionally co-varying for cognitive function in terms of Addenbrooke’s Cognitive Examination 
score; the laterality of dominantly affected side (p > 0.5 for the coefficients of both variables); or when entering 
Direct intercept (c.f. Wolpe et al.19) as the dependent variable. Moreover, when running a similar regression with 
mean Slider force overcompensation as the dependent variable, LDE did not predict overcompensation (indeed, 
unlike the Direct condition, the direction of effect was negative, t15 = −1.432, p = 0.173), whereas disease severity 
was a significant positive predictor (t15 = 2.573, p  <  0.05). As this effect is in the opposite direction to the effect 
observed for Direct overcompensation, a generic effect of disease or drug on sensory, planning or execution 
systems cannot explain the impact of LDE and disease severity on sensory attenuation in the Direct condition. 
Together, these results suggest that dopamine treatment could restore parkinsonism-related reduction in sensory 
attenuation.
As Slider slope differed between groups, we fit a regression model to the Slider slope in a final exploratory 
analysis. Disease severity and LDE were the only independent variables. In this model (F(2,15) = 6.974, p = 0.007; 
41% of variance explained), disease severity was a positive predictor of Slider slope (b = 0.48, t15 = 2.29, p  <  0.05) 
and LDE was a significant negative predictor (b = −0.77, t15 = −3.67, p = 0.002). The results did not change when 
including Direct force overcompensation as an additional covariate, suggesting these results cannot be readily 
explained by performance in the Direct condition.
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Discussion
The principal result of our study is that sensorimotor attenuation is positively related to dopamine doses in 
Parkinson’s disease, whereas disease severity is related to reduced attenuation. These results can be interpreted in 
the context of optimal control theory, in which voluntary actions rely on the integration of sensory feedback with 
predictions of the consequences of one’s actions35. The integration is precision-dependent, such that low-precision 
signals are down-weighted relative to high-precision signals. For example, this means that when performing a 
task in a dark or foggy setting, the precision of sensory feedback is expected to be low, and the sensorimotor 
system therefore relies more strongly on prior predictions when performing an action7. Sensory attenuation is 
thought to reflect the precision of predictive signals36, relative to the precision of sensory feedback14,19. Our find-
ing that PD motor severity is associated with reduced attenuation would therefore suggest that the precision of 
predictive signals may be compromised in PD22. This may underlie the changes of sensorimotor integration in 
PD37 and the dependence of patients on sensory cues, e.g. for the initiation and maintenance of their movement12.
Although the severity of parkinsonism and doses of dopamine replacement therapy were positively correlated, 
dopamine was associated with an opposite effect, namely increased attenuation. These results support the hypoth-
esis that dopamine alleviates disorders of movement in PD by restoring the precision and hence the typical reli-
ance on sensorimotor predictions22, at the expense of down-weighting the sensorium. This is further supported 
by the finding that an increase in dopamine dose was related to reduced force sensitivity in the Slider condition, 
reflecting reduced precision afforded to sensory signals. Finally, these results are further consistent with the exag-
geration of age-related sensory deficits in medicated PD patients33, and the detrimental effects of dopaminergic 
therapy on sensory sensitivity in PD38,39. However, conflicting data on this issue exist40, and some studies revealed 
no adverse effect of dopamine on tactile perception, at least in terms of perceptual thresholds41.
The relationship between dopamine and the integration prediction with sensory information has been previ-
ously tested in PD. For example, dopamine increases the perceived temporal attraction or ‘binding’ between an 
action and its effect42 (but also see ref.43). As binding critically relies on sensorimotor prediction44,45, these results 
are consistent with the hypothesis that dopamine increases the reliance on sensorimotor prediction for action. 
Importantly, however, other studies reported the opposite association, in which dopaminergic treatment reduced 
the reliance on predictions in perceptual decision-making tasks, while increasing reliance on sensory informa-
tion9,10. We propose that these are different types of predictions that are mediated by distinct brain mechanisms 
within a cortical hierarchy (c.f. Brown et al.14). “Low-level” sensorimotor predictions reflected in sensory atten-
uation depend on pre-SMA connectivity with dorsal striatum circuits19, and could play a key role in normal exe-
cution of movement14,22. On the other hand, high-level perceptual priors depend more on prefrontal connections 
with ventral striatum circuitry46,47. Since dopamine doses are tailored to alleviate patient motor symptoms, which 
mostly reflect dorsal striatal dopamine depletion, high dopamine doses can effectively “overdose” the ventral 
striatum48. This discrepancy might lead to the relative normalisation of low-level predictions for attenuation, but 
a weakening of high-level predictions for perceptual decision-making tasks10.
The positive association between attenuation and dopamine, and the combination of increased Direct inter-
cept and reduced Slider slope in medicated PD patients mirror the impact of healthy ageing on sensory attenua-
tion19. Increased attenuation found with normal ageing is associated with reduced connectivity in a fronto-striatal 
network19 that is strongly affected in PD. This network includes the caudate and putamen, dorsolateral prefron-
tal cortex and pre-SMA as the network hub. Interestingly, reduced fronto-striatal connectivity has also been 
Figure 3. Association between dopamine and patient attenuation. (A) Illustration of the standardised beta 
estimates of all independent variable coefficients included in the multiple regression model (R2adj = 0.40), 
predicting Direct intercept. Clinical variables of interest were disease severity, which had a negative effect on 
attenuation, and levodopa doses, which had a positive effect on attenuation. Error bars indicate ± 1 standard 
error of group mean. LDE = Levodopa dose equivalent. Significance level indicated by *P  <  0.05; **P  <  0.01; 
ns = non-significant. (B) Illustration of the relationship between Direct force overcompensation and levodopa 
dose equivalent, before entered into the regression model.
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associated with increased caudate dopamine synthesis as seen in healthy ageing49. Therefore, increasing dopamine 
synthesis – including by levodopa administration in PD – could increase sensory attenuation by altering connec-
tivity of the pre-SMA within its fronto-striatal network.
Activity in the secondary somatosensory cortex, mediated via increased pre-SMA connectivity19,50, has also 
been suggested as the neural correlates of attenuation. Neurophysiological studies have indeed demonstrated 
that the perceived attenuation is closely related to late components of sensory evoked potentials, arising from the 
secondary somatosensory cortex51. In PD, however, early components of sensory evoked potentials, arising from 
fronto-striatal activity, are already altered37. The typical neurophysiological attenuation of these early components 
following a voluntary movement is absent in PD patients ‘off ’ medication, and restored by dopamine treatment22. 
This reduced neurophysiological attenuation of the early components of sensory evoked potential has been attrib-
uted to a failure in sensory ‘gating’ in PD22, resulting from abnormal precision of sensory afferents14.
The neurophysiological gating of sensory afferent signals before and during movement has been proposed 
to be required for the initiation processes of voluntary movements14,52. This theoretical account suggests that a 
relative reduction in the precision of sensory signals, leading to sensory attenuation, enables high-level predic-
tions to drive normal movement through hierarchical networks in the central nervous system14. In PD, deficient 
precision of predictions would be overwhelmed by sensory evidence for a lack of movement, resulting in brady-
kinesia14. Although the neurophysiological attenuation of early components of sensory evoked potentials, shown 
to be impaired in PD and remediated with dopamine, may not directly underlie the behavioural phenomenon 
of attenuation51, our behavioural results are consistent with these previous studies. Our findings that PD motor 
severity is associated with reduced attenuation while dopamine dose is related to increased attenuation, support 
the hypothesis that bradykinesia in Parkinson’s disease could be considered in terms of pathological imprecision 
of sensorimotor prediction, which are alleviated by dopamine treatment.
Our results have two main interpretative limitations that should be considered. Firstly, we opted for the force 
matching task, as it is a simple, highly intuitive and robust task19, however, it requires the application of (albeit 
small) forces for matching the perceived pressure intensities. Preliminary testing indeed showed that the task 
is not easily performed by PD patients ‘off ’ medication, mainly because of tremor and akinesia in light of the 
timed, dexterous movements required for matching the forces. Explicit measures of attenuation such as intensity 
ratings (e.g.53) may go around patient motor difficulties, but introduce additional confounders due to cognitive 
and metacognitive difficulties in patients. We therefore included only an ‘on’ state, in which patients were well 
able to generate forces (even larger forces on average, see Fig. 2). Further, we accounted for differences in motor 
outflow by: (1) using a moving average method that captures the time window with the lowest variability in 
matched force; time windows that were revealed to be similar across groups. (2) performing several control anal-
yses revealing that matching procedure was not significantly altered in patients. (3) accounting for differences in 
motor abilities in the main analysis linking attenuation and levodopa and disease severity.
Secondly, PD patients can show intrinsic sensory deficits41, and differences in sensory inflow must therefore 
be ruled out as a potential confound. In a matching task any absolute bias is factored out and therefore sensory 
deficits, which are common in PD33,41, can increase performance variability, as observed in our study, but are 
unlikely to introduce a systematic bias (e.g. with a force of ‘X’ N sensed as X/2N, patients would still have to 
match X N to experience the same X/2N intensity). Performance in the control Slider condition indeed showed 
a minimal bias, similar to controls, but it also suggested reduced sensory sensitivity. Similarly, unexplained vari-
ance of matched versus target force in the Direct condition was increased in patients, suggesting reduced sensory 
precision19. Importantly, however, these sensory differences in patients (measured as Slider slope and Direct 
unexplained variance) were accounted for in the main regression analyses, suggesting that sensory deficits were 
unlikely to provide a sufficient explanation for the significant associations between attenuation, disease severity 
and dopamine dose.
In conclusion, our study suggests that dopamine is related to an increase in sensory attenuation in Parkinson’s 
disease, and that dopamine increases the precision of sensorimotor prediction for movement. We propose that 
dopamine has distinct effects for representing sensory uncertainty in perceptual decision-making and motor con-
trol. The results support the hypothesis that bradykinesia in movement disorders like Parkinson’s disease can, in 
part, be considered in terms of pathological (im)precision of sensorimotor predictions14, which can be modulated 
by dopamine22. This may provide a common framework for understanding the role of dopamine in perceptual, 
cognitive and motor function.
Data Availability
Patient data and analysis code are available from the corresponding author upon request. Cam-CAN raw data and 
analysis code are available upon signing a data sharing request form (http://www.mrc-cbu.cam.ac.uk/datasets/
camcan/).
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